Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249808 | 0.85 | VCAM1 (0.76) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL9307787 | 0.85 | VCAM1 (0.81) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL4604303 | 0.85 | VCAM1 (0.81) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL18249860 | 0.84 | VCAM1 (0.61) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL18249793 | 0.82 | VCAM1 (0.66) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL1258621 | 0.82 | VCAM1 (1.00) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL8625340 | 0.80 | VCAM1 (0.96) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| 4-Chloro-3-Nitrobenzoic Acid SCHEMBL6101 | 0.80 | VCAM1 (0.77) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| 4-Chloro-3-Nitrobenzoic Acid SCHEMBL30234086 | 0.80 | VCAM1 (0.77) | VCAM1ALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL9524519 | 0.80 | VCAM1 (0.81) | VCAM1ALDH1A1MAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298005-B1 | ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11708352-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-25 | — | — | US | disclosed |
| US-11149025-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210009562-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10562886-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180354932-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-12-13 | — | — | US | disclosed |
| EP-3298005-A2 | ANTI-CANCER COMPOUNDS | The Regents of The University of California (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187620-A2 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-24 | — | — | WO | disclosed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562886-B2 | Anti-cancer compounds | TP53, VHL, BAD | VCAM1 2530/4885ALDH1A1 793/4885MAPT 2150/4885 |
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | VCAM1 425/4885ALDH1A1 2799/4885MAPT 3802/4885 |
| US-20180354932-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | VCAM1 2530/4885ALDH1A1 793/4885MAPT 2150/4885 |
| US-20210009562-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | VCAM1 2530/4885ALDH1A1 793/4885MAPT 2150/4885 |
| US-11708352-B2 | Anti-cancer compounds | TP53, VHL, BAD | VCAM1 2530/4885ALDH1A1 793/4885MAPT 2150/4885 |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | VCAM1 2530/4885ALDH1A1 793/4885MAPT 2150/4885 |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | VCAM1 669/4885ALDH1A1 2219/4885MAPT 4711/4885 |
| US-11149025-B2 | Anti-cancer compounds | TP53, VHL, BAD | VCAM1 2530/4885ALDH1A1 793/4885MAPT 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.